Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
And AbbVie and Genmab scoop their ASH presentation with new data.
But Enhertu is coming.
The restructured biotech’s new lead project enters phase 1.
A new first-line maintenance phase 3 joins a relapsed pivotal phase 2 study.
But neladalkib results worsen, and come with a red flag about liver enzyme elevations.
The private biotech adds another asset to J&J’s prostate cancer pipeline.
